RSV investigational vaccines

Paused developmental vaccine candidates
Respiratory syncytial virus (RSV) Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
Respiratory syncytial virus (RSV)
 
Phase 3
Infants via maternal immunization*
Respiratory diseases
Respiratory syncytial virus (RSV)
 
Phase 1
Children between 2−6 years old
Respiratory diseases
Respiratory syncytial virus (RSV)
 
Phase 1
Adults 60+ years old*
Matrix-M™ adjuvant
Therapeutic area
Respiratory diseases
Infectious disease
Respiratory syncytial virus (RSV)
Status
 
Phase 3
Infants via maternal immunization*
Technology
Status
 
Phase 1
Children between 2−6 years old
Technology
Status
 
Phase 1
Adults 60+ years old*
Technology
Matrix-M™ adjuvant

About the candidates

RSV fusion (RSV F) recombinant protein nanoparticle investigational vaccines with or without aluminum phosphate or Matrix-M™ as an adjuvant.

Why it matters

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants, young children, and older adults worldwide, causing over 3.2 million hospitalizations in children and 336,000 hospitalizations in adults ≥65 years of age.1,2 The development of RSV vaccines has been identified as a priority for WHO's Vaccine Product and Delivery Research Unit.3

This trial did not meet its primary endpoint.
  1. Verwey C, Nunes M. Lancet Glob Health. 2020;8:1247–1248.
  2. Shi T, et al. J Infect Dis.. 2020;222:577–583.
  3. Respiratory Syncytial Virus (RSV). WHO. Available at: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/respiratory-syncytial-virus-(rsv) [Accessed 3 Sept 2021].